Collection and Cryopreservation of Plasmodium falciparum Clinical Isolates in the Field

Partey, Frederica Dedo; Frimpong, Augustina; Ofori, Michael F.

doi:10.1007/978-1-0716-2189-9_2

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As opposed to laboratory strains, clinical isolates often have multiple parasite genotypes (clones) with different drug-resistant phenotypes that can affect the efficacy of an antimalarial compound. Consequently, it is essential to validate their potency using clinical isolates to prioritize these compounds for clinical applications (Chirawurah et al, 2017;Partey et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

MMV006087 is a potent Malaria Box compound against Plasmodium falciparum clinical parasites

Chirawurah,

Adikah,

Ansah

et al. 2023

Front. Drug Discov.

View full text Add to dashboard Cite

The emergence of drug-resistant malaria parasites to artemisinin and its partner drugs highlights the need to increase the arsenal of new antimalarials with novel mechanisms of action. To help achieve this aim, this study tested the potency of three Malaria Box compounds (MMV006087, MMV085203, and MMV008956) against five laboratory strains and twenty clinical isolates of Plasmodium falciparum using optimized in vitro growth inhibitory assays. The results were compared to the response from four standard antimalarials-artesunate, chloroquine, mefloquine, and halofantrine. From the results, MMV006087 was the most potent compound with an average IC50 of 22.13 nM compared to MMV085203 (average IC50 of 137.90 nM) and MMV008956 (average IC50 of 262.30 nM). On average, the laboratory strains were also less susceptible to the three Malaria Box compounds (average IC50 of 162.30 nM) compared to the clinical isolates (average IC50 of 135.40 nM). Additionally, MMV006087 was less potent than artesunate but twice more efficacious than chloroquine against the laboratory strains and clinical isolates. The data from this study validate the potency of MMV006087 and MMV085203 as promising antimalarials worthy of further exploration. This study further substantiates the need to include clinical isolates in antimalarial compound screening activities.

show abstract

Section: Introductionmentioning

confidence: 99%